

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	37
1.2 Alpelisib (Piqray)	Less than 5
1.3 Elacestrant (Orserdu)	Less than 5
1.4 Fulvestrant (fulvestrant or Faslodex)	9
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	30
1.7 Ribociclib (Kisqali)	22
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	Less than 5

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	23
2.2 Ribociclib (Kisqali)	Less than 5
2.3 Olaparib (Lynparza)	Less than 5

Q3. How many patients received the following medicines with **curative** treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	20
3.2 Ribociclib (Kisqali)	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	Less than 5
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	Less than 5
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	Less than 5

Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025?

Type of breast cancer	Number patients treated
5.1 Olaparib - All types of breast cancer	Less than 5
5.2 Olaparib - Locally advanced or metastatic breast cancer	Less than 5
5.3 Talazoparib – All types of breast cancer	0

Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	Less than 5
6.2 Pertuzumab with Trastuzumab (Phesgo)	21
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	21
6.4 Trastuzumab Deruxtecan (EnHertu)	5
6.5 Trastuzumab Emtansine (Kadcyla)	Less than 5
6.6 Tucatinib (Tukysa)	Less than 5
6.7 Neratinib (Nerlynx)	0

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (*ICD-10 codes = C50*, D509*) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	19
7.2 Trastuzumab Deruxtecan (EnHertu)	5

Q8. How many patients received the following products with **curative treatment intent** in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	Less than 5
8.2 Pertuzumab with Trastuzumab (Phesgo)	8
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	11
8.4 Trastuzumab Emtansine (Kadcyla)	Less than 5

Q9. How many patients received the following products as part of **neoadjuvant** or **adjuvant** therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)	0	Less than 5	Less than 5
9.2 Pertuzumab with Trastuzumab (Phesgo)	6	Less than 5	8
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	Less than 5	10	11
9.4 Trastuzumab Emtansine (Kadcyla)	0	Less than 5	Less than 5

Q10. How many patients received **trastuzumab deruxtecan (Enhertu)** for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	5
10.2 HER2-low Breast Cancer	0

Q11. How many patients were treated for the following **indications for metastatic HER2+ve breast cancer** by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available?

Name of medicine	Line of Therapy (indication)	Number patients treated
11.1 Trastuzumab Deruxtecan (Enhertu)	Following one or more prior anti-HER2-based regimens	Less than 5
11.2 Trastuzumab Deruxtecan (Enhertu)	Following one prior anti HER2-based regimen	Less than 5
11.3 Trastuzumab Emtansine (Kadcyla)	Following one or more prior anti-HER2-based regimens	0
11.4 Trastuzumab Emtansine (Kadcyla)	Following one prior anti HER2-based regimen	0
11.5 Trastuzumab	Following one or more prior anti-HER2-based regimens	Less than 5
11.6 Trastuzumab	Following one prior anti HER2-based regimen	Less than 5